Episurf Medical AB (publ) (EPIS-B) - Net Assets
Based on the latest financial reports, Episurf Medical AB (publ) (EPIS-B) has net assets worth Skr47.50 Million SEK (≈ $5.11 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr59.80 Million ≈ $6.44 Million USD) and total liabilities (Skr12.30 Million ≈ $1.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EPIS-B financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr47.50 Million |
| % of Total Assets | 79.43% |
| Annual Growth Rate | 29.49% |
| 5-Year Change | -81.21% |
| 10-Year Change | -2.46% |
| Growth Volatility | 304.18 |
Episurf Medical AB (publ) - Net Assets Trend (2009–2025)
This chart illustrates how Episurf Medical AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore Episurf Medical AB (publ) balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Episurf Medical AB (publ) (2009–2025)
The table below shows the annual net assets of Episurf Medical AB (publ) from 2009 to 2025. For live valuation and market cap data, see market value of Episurf Medical AB (publ).
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr47.50 Million ≈ $5.11 Million |
-43.32% |
| 2024-12-31 | Skr83.80 Million ≈ $9.02 Million |
-0.83% |
| 2023-12-31 | Skr84.50 Million ≈ $9.09 Million |
-52.45% |
| 2022-12-31 | Skr177.70 Million ≈ $19.12 Million |
-29.71% |
| 2021-12-31 | Skr252.80 Million ≈ $27.21 Million |
+49.14% |
| 2020-12-31 | Skr169.50 Million ≈ $18.24 Million |
+309.42% |
| 2019-12-31 | Skr41.40 Million ≈ $4.46 Million |
-7.59% |
| 2018-12-31 | Skr44.80 Million ≈ $4.82 Million |
-47.65% |
| 2017-12-31 | Skr85.57 Million ≈ $9.21 Million |
+75.72% |
| 2016-12-31 | Skr48.70 Million ≈ $5.24 Million |
-55.70% |
| 2015-12-31 | Skr109.93 Million ≈ $11.83 Million |
+182.97% |
| 2014-12-31 | Skr38.85 Million ≈ $4.18 Million |
-45.75% |
| 2013-12-31 | Skr71.61 Million ≈ $7.71 Million |
+193.60% |
| 2012-12-31 | Skr24.39 Million ≈ $2.62 Million |
-49.71% |
| 2011-12-31 | Skr48.50 Million ≈ $5.22 Million |
+398.09% |
| 2010-12-31 | Skr9.74 Million ≈ $1.05 Million |
+1181.64% |
| 2009-12-31 | Skr759.76K ≈ $81.76K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Episurf Medical AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 81315975900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr16.60 Million | 34.95% |
| Other Components | Skr844.60 Million | 1778.11% |
| Total Equity | Skr47.50 Million | 100.00% |
Episurf Medical AB (publ) Competitors by Market Cap
The table below lists competitors of Episurf Medical AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Commcenter S.A.
MC:CMM
|
$11.41 Million |
|
e-future.Co.Ltd
KQ:134060
|
$11.41 Million |
|
Educational Development Corporation
NASDAQ:EDUC
|
$11.42 Million |
|
Ducon Infratechnologies Limited
NSE:DUCON
|
$11.42 Million |
|
Wizz Air Holdings PLC
LSE:WIZZ
|
$11.41 Million |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
$11.41 Million |
|
Highfield Resources Ltd
AU:HFR
|
$11.40 Million |
|
Taruga Minerals Ltd
AU:TAR
|
$11.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Episurf Medical AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 83,800,000 to 47,500,000, a change of -36,300,000 (-43.3%).
- Net loss of 58,200,000 reduced equity.
- Share repurchases of 29,700,000 reduced equity.
- New share issuances of 29,700,000 increased equity.
- Other comprehensive income increased equity by 100,000.
- Other factors increased equity by 21,800,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-58.20 Million | -122.53% |
| Share Repurchases | Skr29.70 Million | -62.53% |
| Share Issuances | Skr29.70 Million | +62.53% |
| Other Comprehensive Income | Skr100.00K | +0.21% |
| Other Changes | Skr21.80 Million | +45.89% |
| Total Change | Skr- | -43.32% |
Book Value vs Market Value Analysis
This analysis compares Episurf Medical AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.83x to 1.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | Skr0.08 | Skr0.06 | x |
| 2010-12-31 | Skr1.21 | Skr0.06 | x |
| 2011-12-31 | Skr2.18 | Skr0.06 | x |
| 2012-12-31 | Skr1.10 | Skr0.06 | x |
| 2013-12-31 | Skr2.04 | Skr0.06 | x |
| 2014-12-31 | Skr1.09 | Skr0.06 | x |
| 2015-12-31 | Skr2.73 | Skr0.06 | x |
| 2016-12-31 | Skr1.05 | Skr0.06 | x |
| 2017-12-31 | Skr1.25 | Skr0.06 | x |
| 2018-12-31 | Skr0.70 | Skr0.06 | x |
| 2019-12-31 | Skr0.32 | Skr0.06 | x |
| 2020-12-31 | Skr0.55 | Skr0.06 | x |
| 2021-12-31 | Skr0.59 | Skr0.06 | x |
| 2022-12-31 | Skr0.35 | Skr0.06 | x |
| 2023-12-31 | Skr0.18 | Skr0.06 | x |
| 2024-12-31 | Skr0.17 | Skr0.06 | x |
| 2025-12-31 | Skr0.05 | Skr0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Episurf Medical AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -122.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -431.11%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.26x
- Recent ROE (-122.53%) is below the historical average (-74.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -71.11% | 0.00% | 0.00x | 1.59x | Skr-616.22K |
| 2010 | -28.61% | 0.00% | 0.00x | 1.16x | Skr-3.76 Million |
| 2011 | -9.19% | 0.00% | 0.00x | 1.04x | Skr-9.31 Million |
| 2012 | -64.65% | 0.00% | 0.00x | 1.14x | Skr-18.21 Million |
| 2013 | -31.92% | -60282.45% | 0.00x | 1.07x | Skr-30.02 Million |
| 2014 | -84.72% | -19022.82% | 0.00x | 1.11x | Skr-36.80 Million |
| 2015 | -40.00% | -4326.25% | 0.01x | 1.08x | Skr-54.97 Million |
| 2016 | -126.63% | -2563.48% | 0.04x | 1.24x | Skr-66.54 Million |
| 2017 | -71.40% | -2453.31% | 0.03x | 1.09x | Skr-69.65 Million |
| 2018 | -129.02% | -1445.00% | 0.07x | 1.22x | Skr-62.28 Million |
| 2019 | -170.53% | -1440.82% | 0.09x | 1.39x | Skr-74.74 Million |
| 2020 | -38.11% | -1292.00% | 0.03x | 1.09x | Skr-81.55 Million |
| 2021 | -27.49% | -1069.23% | 0.02x | 1.07x | Skr-94.78 Million |
| 2022 | -43.50% | -1171.21% | 0.03x | 1.11x | Skr-95.07 Million |
| 2023 | -112.19% | -920.39% | 0.10x | 1.23x | Skr-103.25 Million |
| 2024 | -90.69% | -584.62% | 0.13x | 1.17x | Skr-84.38 Million |
| 2025 | -122.53% | -431.11% | 0.23x | 1.26x | Skr-62.95 Million |
Industry Comparison
This section compares Episurf Medical AB (publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $171,567,428
- Average return on equity (ROE) among peers: -27.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Episurf Medical AB (publ) (EPIS-B) | Skr47.50 Million | -71.11% | 0.26x | $11.41 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Episurf Medical AB (publ)
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It offers Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesio… Read more